Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anandamide is an endogenous lipid mediator, classified as an endocannabinoid, structurally described as arachidonylethanolamide. It acts as an agonist of cannabinoid receptors, especially cannabinoid receptor 1 (CB1) and, to a lesser extent, cannabinoid receptor 2 (CB2), and can also interact with other molecular targets such as G protein–coupled receptor 55 (GPR55). Anandamide is synthesized in the brain and other animal tissues and participates in physiological processes including pain regulation, mood, appetite, memory, and modulation of the hypothalamic–pituitary–adrenal (HPA) axis. Unlike classic neurotransmitters, anandamide is produced on demand from membrane phospholipid precursors. After release and action, it is rapidly degraded by fatty acid amide hydrolase (FAAH). It is not an approved pharmaceutical, but is widely used as a research tool to study the endocannabinoid system[1][2][3][5][6][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anandamide.